ロード中...
Joint action of miR‐126 and MAPK/PI3K inhibitors against metastatic melanoma
Emerging data support the rationale of combined therapies in advanced melanoma. Specifically, the combined use of drugs with different mechanisms of action can reduce the probability of selecting resistant clones. To identify agents active against melanoma cells, we screened a library of 349 anti‐ca...
保存先:
| 出版年: | Mol Oncol |
|---|---|
| 主要な著者: | , , , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
John Wiley and Sons Inc.
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6717748/ https://ncbi.nlm.nih.gov/pubmed/31115969 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/1878-0261.12506 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|